Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neurological Sciences
Published in: Neurological Sciences 1/2018

01-06-2018 | Review Article

What the pharmacological management of migraine can tell us about the future of migraine patient care

Author: Paul B. Rizzoli

Published in: Neurological Sciences | Special Issue 1/2018

Login to get access

Abstract

Some of the principles of the pharmacologic management of migraine are echoed in urgent discussions of the future of headache care in the USA and around the world. From adverse events to tolerance, addiction, medication overuse and medication persistence, solutions to the pathophysiologic puzzles, and management difficulties in migraine can be found by paying closer attention to patient reports and by facilitating greater patient involvement in the treatment process. Similarly, listening to the patient as customer in the process of value-based care, so adaptable for the problem of migraine, is the solution to the health care crisis we face in so many countries.
Literature
1.
Nebeker JR, Barach P, Samore MH (2004) Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann Intern Med 140(10):795–801PubMedCrossRef
2.
3.
O’Brien, Charles P (2001) Chapt 24 Drug Addiction and Drug Abuse. In: Hardman JG and Limbird, LE (eds.) Goodman and Gilman’s the pharmacological basis of therapeutics, 10th edn. McGraw-hill, pp 621-642
4.
O’Brien, Charles P (2001) Chapt 24 Drug Addiction and Drug Abuse. In: Hardman JG and Limbird, LE (eds.) Goodman and Gilman’s the pharmacological basis of therapeutics, 10th edn. McGraw-hill, p 624
5.
Rizzoli P, Loder E (2011) Tolerance to the beneficial effects of prophylactic migraine drugs: a systematic review of causes and mechanisms. Headache 51:1323–1335PubMedCrossRef
6.
Schuckit MA, Smith TL (1996) An 8-year follow-up of 450 sons of alcoholic and control subjects. Arch Gen Psychol 53:202–210CrossRef
7.
Domingues et al (2014) Alcohol use problems in migraine and tension-type headache. Arq Neuropsiquiatr 72(1):24–27PubMedCrossRef
8.
Skobic H et al (2010) Prevalence of alcohol abuse and alcoholism in general population of Mostar region, Bosnia and Herzegovina. Coll Antropol 34(Suppl 1):29–31PubMed
9.
Zlotnik Y, Plakht Y, Aven A, Engel Y, Am NB, Ifergane G (2014 Apr) Alcohol consumption and hangover patterns among migraine sufferers. J Neurosci Rural Pract 5(2):128–134PubMedPubMedCentralCrossRef
10.
Loder E (2002 Oct) What is the evolutionary advantage of migraine? Cephalalgia 22(8):624–632CrossRef
11.
Scher AI, Rizzoli PB, Loder EW (2017) Medication overuse headache: an entrenched idea in need of scrutiny. Neurology 89:1–9CrossRef
12.
Biondi DM (2003) Opioid resistance in chronic daily headache: a synthesis of ideas from the bench and bedside. Curr Pain Headache Rep 7:67–75PubMedCrossRef
13.
Jackson JL, Cogbill E, Santana-Davila R, Eldredge C, Collier W, Gradall A, Sehgal N, Kuester J (2015) A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. PLoS One 10:e0130733PubMedPubMedCentralCrossRef
14.
Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P, Hansen RN, Devine EB (2017) Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia 37(5):470–485PubMedCrossRef
15.
Turner DP, Golding AN, Houle TT (2016 Oct) Using a graphical risk tool to examine willingness to take migraine prophylactic medications. Pain 157(10):2226–2234PubMedPubMedCentralCrossRef
16.
Berger A, Bloudek LM, Varon SF, Oster G (2012 Sep) Adherence with migraine prophylaxis in clinical practice. Pain Pract 12(7):541–549PubMedCrossRef
17.
Hepp Z, Bloudek LM, Varon SF (2014) Systemic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm 20(1):22–33PubMedCrossRef
18.
Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB (2015) Adherence to oral migraine preventive medications among patients with chronic migraine. Cephalalgia 35:478–488PubMedCrossRef
19.
Luykx et al (2009) Are migraineurs at increased risk of adverse drug responses? A meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine. Clin Pharmacol Ther 85(3):283–288PubMedCrossRef
20.
Attar HS, Chandramani S (2012 Aug) Impact of physician empathy on migraine disability and migraineur compliance. Ann Indian Acad Neurol 15(Suppl 1):S89–S94PubMedPubMedCentralCrossRef
21.
Katić BJ, Krause SJ, Tepper SJ, Hu HX, Bigal ME (2010 Jan) Adherence to acute migraine medication: what does it mean, why does it matter? Headache 50(1):117–129PubMedCrossRef
22.
Doyle Strauss L, Weizenbaum E, Loder EW, Rizzoli PB (2016 Nov) Amitriptyline dose and treatment outcomes in specialty headache practice: a retrospective cohort study. Headache 56(10):1626–1634PubMedCrossRef
23.
Ruiz MA, Pardo A, Rejas J, Soto J, Villasante F, Aranguren JL (2008 Sep-Oct) Development and validation of the “Treatment Satisfaction with Medicines Questionnaire” (SATMED-Q). Value Health 11(5):913–926PubMedCrossRef
24.
Krska J, Katusiime B, Corlett SA (2017) Validation of an instrument to measure patients’ experiences of medicine use: the Living with Medicines Questionnaire. Patient Prefer Adher 11:671–679CrossRef
25.
Atkinson MJ et al (2004) Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2:12PubMedPubMedCentralCrossRef
26.
Kaplan RS, Porter, ME (2011) How to solve the cost crisis in health care. HBS#R1109B Harvard Business Review. HBR.org
27.
28.
Huckman RS, Kelley MA (2013) Public reporting, consumerism, and patient empowerment. NEJM 369(20):1875–1877PubMedCrossRef
29.
Porter, Lee (2013) The strategy that will fix health care. Harvard Business Review. HBS# R1310B HBR.org. Accessed on Oct
30.
Metadata
Title
What the pharmacological management of migraine can tell us about the future of migraine patient care
Author
Paul B. Rizzoli
Publication date
01-06-2018
Publisher
Springer International Publishing
Published in
Neurological Sciences / Issue Special Issue 1/2018
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-018-3338-x

Other articles of this Special Issue 1/2018

Neurological Sciences 1/2018 Go to the issue

MANAGEMENT AND THERAPY

May migraine attack response to triptans be a predictor of the efficacy of Onabotulinum toxin-A prophylaxis?

PEDIATRIC HEADACHE

Mindfulness meditation for chronic migraine in pediatric population: a pilot study

MIGRAINE PATHOGENESIS

What have we learned from genetic of migraine?

EPIDEMIOLOGY AND BURDEN OF HEADACHE

The use of MIDAS in patients with chronic migraine and medication-overuse headache: should we trust it?

EPIDEMIOLOGY AND BURDEN OF HEADACHE

Personality traits in migraineurs: a case-control study by personality inventory for DSM-5 (PID-5)

EPIDEMIOLOGY AND BURDEN OF HEADACHE

Value of treatment of headache patients and need to improve headache patients’ journey